AC
VRTX icon

ASB Consultores’s Vertex Pharmaceuticals VRTX Stock Holding History

ASB Consultores’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-608
Closed -$271K – 140
2025
Q2 		$271K Buy
608
+32
+6% +$14.7K 0.18% 100
2025
Q1 		$279K Sell
576
-174
-23% -$81.1K 0.18% 84
2024
Q4 		$302K Sell
750
-203
-21% -$94.1K 0.13% 144
2024
Q3 		$443K Buy
953
+163
+21% +$78.3K 0.17% 93
2024
Q2 		$370K Sell
790
-468
-37% -$203K 0.13% 106
2024
Q1 		$526K Buy
+1,258
New +$532K 0.14% 111

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ASB Consultores's VRTX Position: Q3 2025 in Review

ASB Consultores sold out of Vertex Pharmaceuticals (VRTX) in Q3 2025, closing a stake of 608 shares — an estimated $271K sold.

ASB Consultores first reported a position in VRTX in Q1 2024 and held it in 6 quarters. The position peaked at $526K in Q1 2024. 1,519 funds tracked by Wall St. Rank hold VRTX as of Q3 2025.

  • ASB Consultores reported no remaining Vertex Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • ASB Consultores sold 608 Vertex Pharmaceuticals shares in Q3 2025, an estimated $271K.
  • ASB Consultores first reported a position in Vertex Pharmaceuticals in Q1 2024 and held it in 6 quarters.
  • ASB Consultores's Vertex Pharmaceuticals position peaked at $526K in Q1 2024.
  • 1,519 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2025.

Based on ASB Consultores's 13F filing for Q3 2025, filed 4 Nov 2025.